NICE guidance supports the use of imatinib (400mg/day) for the first-line treatment of unresectable and/or metastatic GISTs) but it is not recommended for adjuvant treatment after surgery. Sunitinib is also recommended by NICE as a treatment option for unresectable and/or metastatic malignant GIST (exclusion criteria apply).